Trial results

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

NCT07400588 on ClinicalTrials.gov · last registry update 2026-04-27

Closed to new participants; the 58 already enrolled are still being followed. Its estimated completion date, September 2026, has passed with no update to the record. Primary outcome, as filed: Incidence, severity and relationship of AEs/SAEs. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

aleniglipron

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Sponsor type

Industry

Enrollment

58

Started

2025-12-01

Primary completion

2026-09 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Incidence, severity and relationship of AEs/SAEs

Conditions studied

Obese · Obesity · Obesity Type 2 Diabetes Mellitus · Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.